Website updates

19 July 2007

  • Welcome page
  • “TVM” link in the text does not work.
  • How to Buy/Clinical Training button in top menu bar has spelling mistake in “Clinical” – the second i is missing (this follows through for all pages)
  • Clinical Evidence page
  • Please rename “US Government HTA” to “US Government Health Technology Assessment” and move to go under Randomised Clinical Trials” in the menu bar.
  • Please remove link to training video. Throughout website - we are having problems with getting the sound to work for the website version and will include in the next update.
  • Please insert link to “CMS Decision Memo” under US Government Health Technology Assessment” above.

Therefore menu bar should now read:

The Clinical Evidence

Bibliographies

Real World Case Studies

Randomised Clinical Trials

US Government Health Technology Assessment

CMS Decision Memo

Other

Arrange Training

[The US government… and CMS Decision Memo should open up into the attached downloads. ]

  • Targeted Volume Management page
  • After looking at the graphs, the “back” button should return you to the graphs screen.
  • Please remove training video link
  • US Reimbursement – new page

[This needs to be linked from the How to buy/USA page, from the current US reimbursement link]

“With effect from 22 May 2007, any doctor treating a patient under Medicare or Medicaid is entitled to claim professional reimbursement if they use esophageal Doppler monitoring (EDM) to guide fluid delivery:

  • in patients in intensive care whose breathing is assisted by a ventilator; or
  • in patients undergoing surgery who require fluid management.

CMS reached its decision because it considers using ODM in these groups of patients to be ‘reasonable and necessary’.

This is following the reversal of a pre-existing national coverage determination that specifically excluded reimbursement of esophageal Doppler when used in the CMS patient population.

CMS’s Acting Administer Leslie V. Norwalk commented:

‘(This) decision reflects CMS’ commitment to using evidence-based approaches to provide Medicare beneficiaries with reasonable and necessary medical technologies as they evolve through innovation in the marketplace. As we developed this decision, we used the best available medical evidence-in the form of randomized controlled clinical trials-to re-evaluate our position on this important non-invasive method of caring for patients in intensive care situations.’

CMS’s press release on 22 May 2007 also noted that:

‘In contrast to other techniques for measuring cardiac output, the probe of the esophageal Doppler can be inserted within minutes, requires minimal technical skill, and is not associated with major complications.’

A copy of the CMS commissioned, Health Technology Assessment supporting this decision can be viewed using the link on the right. In addition, a link to the CMS final decision memo is also available here.

[The existing information is a press release for shareholders information and should remain as is on the Welcome page under “Latest Developments” page].

[In the right menu bar there should be the following headings]

US Reimbursement

AHRQ Technology Assessment

CMS Decision Memo.

  • Investor’s relations page
  • Please change “Details of rule 26” to “AIM Rule 26”
  • On Aim Rule 26 front page, need to remove everything except for the first paragraph and replace with:

“All the information required by AIM Rule 26 can be accessed from the links on the right, except for the company announcements for the past twelve months which will be made available on this site shortly”

  • Please change the wording “Committees” to “Board Committees” in the menu bar and the sub page.
  • Please insert “Description of business” as the first heading under the “Other” tab in the menu bar. This should then open to a page with the following text.

“Deltex Medical manufactures and sells medical monitors that are used by doctors and nurses to help patients recover more fully and more quickly from the effects of major surgery.

Deltex Medical is a British company, our products are researched, developed, and designed in the UK and are made at our factory in Chichester, West Sussex.

Multiple clinical trials have consistently demonstrated that using our products to ensure that patients receive the right amount of the right fluid at the right time during their surgery (‘Targeted Volume Management’ or ‘TVM’) reduces complications and means that patients can go home sooner than they otherwise would after their operation.

Deltex Medical’s CardioQ™ monitor is unique in having been proven to be effective in improving patient outcomes and reducing length of hospital stay in repeated, rigorously controlled clinical trials.

To date, more than 300,000 patients have benefited from the use of the CardioQ in surgery and in intensive care and our aim is to establish the use of our products as a ‘standard of care’ for all patients undergoing major surgery or needing monitoring in intensive care.

Our products are manufactured to stringent quality standards, in a controlled environment, by trained technicians and are sold in over thirty countries around the world. The CardioQ and the probes used with it have an industry-leading track record for reliability and safety.”

[This is the same information as on the Welcome page but needs to also be within this section – crazy duplication, but there you go.]